Cannabis use in people with Parkinson's disease and Multiple Sclerosis: A web-based investigation

John H. Kindred, Kaigang Li, Nathaniel B. Ketelhut, Felix Proessl, Brett W. Fling, Justin M. Honce, William R. Shaffer, Thorsten Rudroff

Research output: Research - peer-reviewArticle

Abstract

Objectives Cannabis has been used for medicinal purpose for thousands of years; however the positive and negative effects of cannabis use in Parkinson's disease (PD) and Multiple Sclerosis (MS) are mostly unknown. Our aim was to assess cannabis use in PD and MS and compare results of self-reported assessments of neurological disability between current cannabis users and non-users. Methods An anonymous web-based survey was hosted on the Michael J. Fox Foundation and the National Multiple Sclerosis Society webpages from 15 February to 15 October 2016. The survey collected demographic and cannabis use information, and used standardized questionnaires to assess neurological function, fatigue, balance, and physical activity participation. Analysis of variance and chi-square tests were used for the analysis. Results The survey was viewed 801 times, and 595 participants were in the final data set. Seventy-six percent and 24% of the respondents reported PD and MS respectively. Current users reported high efficacy of cannabis, 6.4 (SD 1.8) on a scale from 0 to 7 and 59% reported reducing prescription medication since beginning cannabis use. Current cannabis users were younger and less likely to be classified as obese (P < 0.035). Cannabis users reported lower levels of disability, specifically in domains of mood, memory, and fatigue (P < 0.040). Conclusions Cannabis may have positive impacts on mood, memory, fatigue, and obesity status in people with PD and MS. Further studies using clinically and longitudinally assessed measurements of these domains are needed to establish if these associations are causal and determine the long-term benefits and consequences of cannabis use in people with PD and MS.

LanguageEnglish (US)
Pages99-104
Number of pages6
JournalComplementary Therapies in Medicine
Volume33
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Fingerprint

Cannabis
Multiple Sclerosis
Parkinson Disease
Surveys and Questionnaires
Fatigue
Chi-Square Distribution
Prescriptions
Analysis of Variance
Obesity
Demography
Self-Assessment
Datasets

Keywords

  • Fatigue
  • Marijuana
  • Memory
  • Mood
  • Obesity
  • Prescription drug use

ASJC Scopus subject areas

  • Complementary and Manual Therapy
  • Complementary and alternative medicine
  • Advanced and Specialized Nursing

Cite this

Cannabis use in people with Parkinson's disease and Multiple Sclerosis : A web-based investigation. / Kindred, John H.; Li, Kaigang; Ketelhut, Nathaniel B.; Proessl, Felix; Fling, Brett W.; Honce, Justin M.; Shaffer, William R.; Rudroff, Thorsten.

In: Complementary Therapies in Medicine, Vol. 33, 01.08.2017, p. 99-104.

Research output: Research - peer-reviewArticle

Kindred, JH, Li, K, Ketelhut, NB, Proessl, F, Fling, BW, Honce, JM, Shaffer, WR & Rudroff, T 2017, 'Cannabis use in people with Parkinson's disease and Multiple Sclerosis: A web-based investigation' Complementary Therapies in Medicine, vol 33, pp. 99-104. DOI: 10.1016/j.ctim.2017.07.002
Kindred, John H. ; Li, Kaigang ; Ketelhut, Nathaniel B. ; Proessl, Felix ; Fling, Brett W. ; Honce, Justin M. ; Shaffer, William R. ; Rudroff, Thorsten. / Cannabis use in people with Parkinson's disease and Multiple Sclerosis : A web-based investigation. In: Complementary Therapies in Medicine. 2017 ; Vol. 33. pp. 99-104
@article{027042a679a64f358fcad096101f8789,
title = "Cannabis use in people with Parkinson's disease and Multiple Sclerosis: A web-based investigation",
abstract = "Objectives Cannabis has been used for medicinal purpose for thousands of years; however the positive and negative effects of cannabis use in Parkinson's disease (PD) and Multiple Sclerosis (MS) are mostly unknown. Our aim was to assess cannabis use in PD and MS and compare results of self-reported assessments of neurological disability between current cannabis users and non-users. Methods An anonymous web-based survey was hosted on the Michael J. Fox Foundation and the National Multiple Sclerosis Society webpages from 15 February to 15 October 2016. The survey collected demographic and cannabis use information, and used standardized questionnaires to assess neurological function, fatigue, balance, and physical activity participation. Analysis of variance and chi-square tests were used for the analysis. Results The survey was viewed 801 times, and 595 participants were in the final data set. Seventy-six percent and 24% of the respondents reported PD and MS respectively. Current users reported high efficacy of cannabis, 6.4 (SD 1.8) on a scale from 0 to 7 and 59% reported reducing prescription medication since beginning cannabis use. Current cannabis users were younger and less likely to be classified as obese (P < 0.035). Cannabis users reported lower levels of disability, specifically in domains of mood, memory, and fatigue (P < 0.040). Conclusions Cannabis may have positive impacts on mood, memory, fatigue, and obesity status in people with PD and MS. Further studies using clinically and longitudinally assessed measurements of these domains are needed to establish if these associations are causal and determine the long-term benefits and consequences of cannabis use in people with PD and MS.",
keywords = "Fatigue, Marijuana, Memory, Mood, Obesity, Prescription drug use",
author = "Kindred, {John H.} and Kaigang Li and Ketelhut, {Nathaniel B.} and Felix Proessl and Fling, {Brett W.} and Honce, {Justin M.} and Shaffer, {William R.} and Thorsten Rudroff",
year = "2017",
month = "8",
doi = "10.1016/j.ctim.2017.07.002",
volume = "33",
pages = "99--104",
journal = "Complementary Therapies in Medicine",
issn = "0965-2299",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Cannabis use in people with Parkinson's disease and Multiple Sclerosis

T2 - Complementary Therapies in Medicine

AU - Kindred,John H.

AU - Li,Kaigang

AU - Ketelhut,Nathaniel B.

AU - Proessl,Felix

AU - Fling,Brett W.

AU - Honce,Justin M.

AU - Shaffer,William R.

AU - Rudroff,Thorsten

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objectives Cannabis has been used for medicinal purpose for thousands of years; however the positive and negative effects of cannabis use in Parkinson's disease (PD) and Multiple Sclerosis (MS) are mostly unknown. Our aim was to assess cannabis use in PD and MS and compare results of self-reported assessments of neurological disability between current cannabis users and non-users. Methods An anonymous web-based survey was hosted on the Michael J. Fox Foundation and the National Multiple Sclerosis Society webpages from 15 February to 15 October 2016. The survey collected demographic and cannabis use information, and used standardized questionnaires to assess neurological function, fatigue, balance, and physical activity participation. Analysis of variance and chi-square tests were used for the analysis. Results The survey was viewed 801 times, and 595 participants were in the final data set. Seventy-six percent and 24% of the respondents reported PD and MS respectively. Current users reported high efficacy of cannabis, 6.4 (SD 1.8) on a scale from 0 to 7 and 59% reported reducing prescription medication since beginning cannabis use. Current cannabis users were younger and less likely to be classified as obese (P < 0.035). Cannabis users reported lower levels of disability, specifically in domains of mood, memory, and fatigue (P < 0.040). Conclusions Cannabis may have positive impacts on mood, memory, fatigue, and obesity status in people with PD and MS. Further studies using clinically and longitudinally assessed measurements of these domains are needed to establish if these associations are causal and determine the long-term benefits and consequences of cannabis use in people with PD and MS.

AB - Objectives Cannabis has been used for medicinal purpose for thousands of years; however the positive and negative effects of cannabis use in Parkinson's disease (PD) and Multiple Sclerosis (MS) are mostly unknown. Our aim was to assess cannabis use in PD and MS and compare results of self-reported assessments of neurological disability between current cannabis users and non-users. Methods An anonymous web-based survey was hosted on the Michael J. Fox Foundation and the National Multiple Sclerosis Society webpages from 15 February to 15 October 2016. The survey collected demographic and cannabis use information, and used standardized questionnaires to assess neurological function, fatigue, balance, and physical activity participation. Analysis of variance and chi-square tests were used for the analysis. Results The survey was viewed 801 times, and 595 participants were in the final data set. Seventy-six percent and 24% of the respondents reported PD and MS respectively. Current users reported high efficacy of cannabis, 6.4 (SD 1.8) on a scale from 0 to 7 and 59% reported reducing prescription medication since beginning cannabis use. Current cannabis users were younger and less likely to be classified as obese (P < 0.035). Cannabis users reported lower levels of disability, specifically in domains of mood, memory, and fatigue (P < 0.040). Conclusions Cannabis may have positive impacts on mood, memory, fatigue, and obesity status in people with PD and MS. Further studies using clinically and longitudinally assessed measurements of these domains are needed to establish if these associations are causal and determine the long-term benefits and consequences of cannabis use in people with PD and MS.

KW - Fatigue

KW - Marijuana

KW - Memory

KW - Mood

KW - Obesity

KW - Prescription drug use

UR - http://www.scopus.com/inward/record.url?scp=85023195521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023195521&partnerID=8YFLogxK

U2 - 10.1016/j.ctim.2017.07.002

DO - 10.1016/j.ctim.2017.07.002

M3 - Article

VL - 33

SP - 99

EP - 104

JO - Complementary Therapies in Medicine

JF - Complementary Therapies in Medicine

SN - 0965-2299

ER -